Canaccord raised the firm’s price target on Natera to $100 from $87 and keeps a Buy rating on the shares. The firm believes the company’s Women’s Health and Oncology franchises are well-positioned for near-term revenue growth. Natera may also announce multiple product and data-related updates, representing attractive catalysts. Due to these factors, Canaccord believes the company remains undervalued and remains a stock to focus on.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- Natera announces next phase of CareDx patent infringement litigation
- Canaccord bullish on Natera growth potential as Medicare extends coverage
- Medicare extends coverage of Natera’s signatera MRD test to ovarian cancer
- NTRA Earnings this Week: How Will it Perform?
- Natera downgraded to Outperform from Strong Buy at Raymond James
